419,734
Participants
Start Date
October 1, 2018
Primary Completion Date
October 1, 2019
Study Completion Date
October 1, 2019
Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
Dipeptidyl peptidase-4 (DPP-4) inhibitors
Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal
Drug Safety and Effectiveness Network, Canada
OTHER
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Canadian Network for Observational Drug Effect Studies, CNODES
OTHER